You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Nomethiazoles Harnessing GABA and NO mimetic activity for Alzheimer's therapy

    SBC: sGC Pharma Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) occurs in one out of eight Americans of age 65 and affects 43% of the elderly over 85. Current FDA-approved drugs only provide symptomatic relief of AD. There is a pressing need to discover newdisease-modifying medications. AD is multifactorial in origin and progression. A drug attenuating several underlying factors is a preferred ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. A Novel Insulin Pathway Agonist for Alzheimer's Disease

    SBC: MEDCHEM PARTNERS LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Even though the association of -amyloid peptide (A ) deposition and Alzheimer's Disease (AD) underpins the major hypothesis for disease progression and possibly causation and several drugs addressing the formation or removal of -amyloid plaques have entered clinical trials, no effective therapy exists to date for AD. This reality calls for new targets th ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): In the United States, around 76,250 new cases of melanoma and 9,180 melanoma-related deaths are predicted for 2012. With the therapeutic options currently available, metastatic melanoma patients face the bleak prospectof at best, 10 month's survival and a one-in-ten chance of surviving for 10 years. Surgery and radiation therapy are the mainstay of treatme ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Clinical Translation of an Anti-Metastatic Antibody for Breast Cancer Therapy

    SBC: FOR-ROBIN, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This proposal aims to develop a novel, highly-specific targeted therapy for treatment of breast cancer. The long-term objective is to convert the proprietary intellectual property, the mouse monoclonal antibody (McAb)JAA-F11, which targets the pancarcinoma Thomsen-Friedenreich antigen (TF-Ag) to a humanized form for use as an adjunct with conventional therapy ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Screens for Novel Agonists/Antagonists of Endocrine Fibroblast Growth Factors

    SBC: AGAVE BIOSYSTEMS INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Agave BioSystems and Professor Makoto Kuro-o at the University of Texas Southwestern Medical Center are proposing a collaborative effort to screen for novel small molecules acting as agonists or antagonists of the Klotho and Klotho- dependent endocrine Fibroblast Growth Factors. The expected outcome of this Phase I effort will be the validation of a high-throug ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. High Yield Human Hepatocyte Isolation

    SBC: ORGAN SOLUTIONS, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): End-stage liver disease claims about 30,000 lives in the US. Many patients become too ill to tolerate liver transplantation, and even if transplantation were indicated, there is a severe shortage of viable donor organsand only 28% of the wait-listed patients receive transplants. Development and translational studies with novel alternatives to organ transplanta ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based Magneti

    SBC: Theragnostic Technologies Inc.            Topic: NIDDK

    Abstract This STTR phase 1 proposal investigates the safety and efficacy of a novel high-performance carbon nanostructure-based magnetic resonance imaging (MRI) contrast agent for the imaging and monitoring of patients with renal failure. Every year, in the US, approximately 20 million people are treated for mild to severe renal failure. A significant number of cases (greater than 50%) related to ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Image-Based Quantification and Analysis of Longitudinal Lung Nodule Deformations

    SBC: Kitware, Inc.            Topic: NIBIB

    DESCRIPTION (provided by applicant): Image-based evaluation of pathologies over time is complicated by variability in image acquisition and patient positioning, deformations due to respiratory and cardiac motion, and the clinical standard in radiology of comparing unaligned images. This application proposes a computational method for longitudinal image analysis that captures, illustrates and quant ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. In-situ, real-time oxygen sensor to monitor the long-term efficacy of aerobicall

    SBC: ChromoSense LLC            Topic: NIEHS

    DESCRIPTION (provided by applicant): Groundwater and soil contamination has been associated with higher incidence of birth defects and cancer. Monitored natural attenuation of contaminants via biodegradation has proven effective in lowering contaminant levels, but these processes depend critically on dissolved oxygen levels. This project proposes to develop a robust oxygen sensor compound with che ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Urinary Biomarkers of Renal Mitochondrial Dysfunction

    SBC: SCHNELLGEN, INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): The long-term goal of this project is to identify and validate biomarkers of mitochondrial dysfunction due to environmental stressors. Diverse acute insults from surgery, trauma, ischemia/reperfusion (I/R) and drug andenvironmental chemical toxicity lead to mitochondrial dysfunction and result in cell injury and death in many organs/tissues (e.g. heart, lung, b ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government